(Press-News.org) (WASHINGTON, March 8, 2023) – Sickle cell disease (SCD), a rare chronic, progressive, life-threatening, inherited blood disorder, often affects individuals with chronic pain that can be debilitating to their quality of life. Yet less than 4% of people living with SCD who experience chronic pain episodes have prescriptions for newer FDA-approved pain-relieving drugs, including l-glutamine, voxelotor, and crizanlizumab, according to a new study published in Blood Advances. Further, researchers found that less than a third of patients with pain episodes have prescriptions for hydroxyurea, a drug commonly taken to reduce pain caused by sickle cell disease.
SCD affects more than 100,000 Americans and an estimated 100 million persons worldwide. According to the Centers for Disease Control and Prevention (CDC), SCD affects one out of every 365 Black or African American births and one out of every 16,300 Hispanic American births. The condition can cause severe pain, joint and organ damage, and stroke. Advances in SCD research have prompted the development of groundbreaking therapies, allowing 93% of young people with SCD to live into adulthood, a statistic marking tremendous progress in disease interventions over the last few decades.
While individuals are now living significantly longer, those with frequent pain episodes still face challenges with quality of life, a barrier that pain-relieving medications intend to relieve.
Prior to 2017, hydroxyurea was the only pain-relieving medication available for patients with sickle cell disease developed to help the body make rounder, less sickled cells, which ultimately aims to reduce the overall number of pain episodes an individual experiences. In the last few years, several new therapies, including l-glutamine, voxelotor, and crizanlizumab, have gained FDA approval. Despite the growing list of options to prevent SCD-associated vaso-occlusive pain episodes, many patients still lack access to and knowledge of these drugs.
“These medications are FDA approved, and yet, patients are very rarely using them. Our findings suggest that roughly 2-4% of patients eligible for these medications have a prescription for one of these medications, and less than 2% are being prescribed combination therapy,” explained Robert Cronin, MD, of The Ohio State University Department of Internal Medicine. “We knew disparities in the use of these drugs existed, but it’s been eye-opening to see just how wide these gaps are.”
To conduct this study, investigators surveyed data collected between 2016-2020 from the IBM Watson MarketScan Administrative billing database. They analyzed inpatient and outpatient data, emergency department encounters, total encounters with an SCD diagnosis, procedure codes, and prescription data. Individuals who had visited a health care provider at least three times and had a confirmed SCD diagnosis were included in the study. Using this data, researchers then assessed patient use of hydroxyurea, l-glutamine, voxelotor, and crizanlizumab, both alone and concurrently, sorting by age group and geographic region.
Researchers found that hydroxyurea was the most prominently prescribed medication (31.5%), followed by l-glutamine (3.2%), then crizanlizumab (2.3%) for vaso-occlusive pain. Voxelotor is only approved for people with lower hemoglobin levels and was prescribed to 2.9% of the population. Authors also found that patients living in rural areas had significantly lower use of medications approved for pain episodes, compared to those in non-rural communities. Finally, less than 3% of the population used any type of combination therapy to treat pain, while 0.3% used combinations of these newer FDA approved treatment options.
Importantly, all patients included in this study had private insurance plans. Most individuals with SCD are covered by public insurance plans, suggesting that these findings may be even more disparate among a more representative population. Further, investigators solely tracked prescription patterns and did not track medication adherence. Understanding how often these medications are utilized after being prescribed could be useful in garnering the full picture of SCD medication inequities.
“I think it is important that we educate both providers and patients about the options that exist to treat their condition,” said Dr. Cronin. “From a provider standpoint, it’s essential that a spectrum of physicians possess knowledge of sickle cell disease and its available treatment options. A lot of patients, especially those living in rural areas, do not always have access to a hematologist. And then from the patient standpoint, providing patient-friendly material that allows them to be knowledgeable about their disease and advocate for themselves can help improve care for this population.”
# # #
Blood Advances (www.bloodadvances.org) publishes more peer-reviewed hematology research than any other academic journal worldwide and is an online only, open access journal of the American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders.
Blood Advances® is a registered trademark of the American Society of Hematology.
Contact:
Kira Sampson, American Society of Hematology
ksampson@hematology.org; 202-499-1796
END
Metastatic breast cancer has no cure and has proven stubbornly resistant to one of the most innovative and promising new cancer treatments: immunotherapy.
Now, researchers at Washington University School of Medicine in St. Louis have identified a way to treat the area surrounding breast tumors that have spread to bone so that such tumors become vulnerable to attack by the body’s immune system. When the researchers boosted the activity of certain immune cells, called T cells and macrophages, these immune cells worked together to clear metastatic breast tumors that had spread to the bones of mice, and continued to eliminate tumor cells ...
Researchers have found a way to predict the behavior of many-body quantum systems coupled to their environment. The work represents a way to protect quantum information in quantum devices, which is crucial for real-world applications of quantum technology.
In a study published in Physical Review Letters, researchers at Aalto University in Finland and IAS Tsinghua University in China report a new way to predict how quantum systems, such as groups of particles, behave when they are connected to the external environment. ...
The nitrate ingested over the course of a person’s adult lifetime through the consumption of tap water and bottled water could be a risk factor for prostate cancer, particularly in the case of aggressive tumours and in younger men. This is the conclusion of a study conducted in Spain and led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by the ”la Caixa” Foundation. The findings have been published in Environmental Health Perspectives.
The study also suggests that diet plays an important role. The researchers found that eating plenty of fibre, fruit/vegetables and vitamin C could reduce the negative effect ...
UNIST and BNK Kyongnam Bank recently held a donation agreement ceremony in pursuit of creating a beautiful, biodiverse, and sustainable kitchen garden on UNIST campus.
A ceremony to commemorate and display gratitude for BNK Kyongnam Bank also took place on Friday, February 24, 2023. As part of its Carbon Neutral Campus Project, UNIST has been implementing a number of projects to improve sustainability on campus and in the surrounding community, including the creation of an ecological garden that ...
A team of researchers has discovered a potential therapeutic that can synergize with existing drugs to more effectively kill certain leukemia cells. The authors published their results on Jan. 19 in the journal Molecular & Cellular Proteomics.
Acute myeloid leukemia is a cancer of developing immune cells. It can manifest in all individuals, including the elderly and children. Only 30% of patients survive beyond five years of diagnosis
Unlike cancers of solid organs, AML is found in bodily fluids, such as blood. Like passengers ...
Each year, more than 3 million people ages 65 and older are treated in emergency departments for fall injuries. Head trauma is the leading cause of serious injury with skull fractures being reported as a serious outcome. According to the 2016 National Trauma Database annual report, females account for 58 percent of these falls.
Because geriatric females have an increased rate of falls and facial fractures, determining if they also are at an increased risk of skull fractures is crucial. Currently, research ...
Researchers from Fudan University, China Europe International Business School, and Peking University published a new Journal of Marketing article that examines how marketers can use different messaging to persuade individuals to contribute to a collective goal. The study addresses the specific question of the type of message—fact-based vs. affected-based—that is more effective in eliciting participation based on how near the goal is to completion.
The study, forthcoming in the Journal ...
It sounds like a party trick: Add water to the clear, licorice-flavored ouzo liquor, and watch it turn cloudy. This “ouzo effect” is an example of an easy way to make highly stable emulsions — or mixtures of liquids that don’t like being together, like vinaigrettes — but nobody has yet fully understood how it works. Now, researchers report in ACS Central Science that the secret may lie in the unique structure of the emulsion’s droplets.
Ouzo is a popular liquor enjoyed throughout Greece, ...
Shane Harper, DMS, PA-C, knows how difficult it is to launch a medical research journal and get it into the orbit of the scientific community. In 2022 he became the founding editor-in-chief for the West Texas Journal of Medicine, which published its inaugural issue in December.
By establishing a medical research publication, Harper and the journal’s editorial board seek to provide an online publication that distributes original medical and health sciences-related research in a forum free of common predatory publication practices to ...
Billions of sea anemones adorn the bottom of the Earth’s oceans — yet they are among the rarest of fossils because their squishy bodies lack easily fossilized hard parts. Now a team of paleontologists has discovered that countless sea anemone fossils have been hiding in plain sight for nearly 50 years.
In a newly published paper in the journal Papers in Palaeontology, University of Illinois Chicago’s Roy Plotnick and colleagues report that fossils long-interpreted ...
